Regulatory Pathways for AI Medical Devices and Software: Navigating the Global Landscape

Rasit Dinc

Rasit Dinc Digital Health & AI Research

Abstract

The integration of Artificial Intelligence AI and Machine Learning ML into medical devices and software is rapidly transforming healthcare, offering unpreced...

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into medical devices and software is rapidly transforming healthcare, offering unprecedented capabilities for diagnosis, treatment, and patient management. However, the dynamic, adaptive nature of these technologies presents unique challenges to traditional regulatory frameworks designed for static devices. For professionals in digital health and AI, understanding the evolving **regulatory pathways for AI medical devices** is crucial for successful market entry and responsible innovation.

The Software as a Medical Device (SaMD) Foundation

The regulatory journey for most AI-enabled health products begins with their classification as **Software as a Medical Device (SaMD)**. This classification, defined by the International Medical Device Regulators Forum (IMDRF), establishes that the software itself is intended to be used for one or more medical purposes without being part of a hardware medical device [1]. AI algorithms that analyze medical images, predict disease risk, or guide treatment decisions typically fall under this umbrella.

The United States: FDA's Adaptive Approach

The U.S. Food and Drug Administration (FDA) has been at the forefront of developing an adaptive regulatory approach to accommodate the unique characteristics of AI/ML-enabled medical devices (AI/ML-DSF).

The 510(k) and De Novo Pathways

The majority of AI/ML-DSFs cleared by the FDA have utilized the **510(k) premarket notification pathway** [2]. This route requires demonstrating that the new device is substantially equivalent to a legally marketed predicate device. For novel AI devices without a predicate, the **De Novo classification request pathway** is used, which establishes a new classification and

regulatory controls [3].

Predetermined Change Control Plans (PCCP)

Recognizing that AI/ML models are designed to learn and change over time, the FDA introduced the concept of the **Predetermined Change Control Plan (PCCP)**. Finalized in late 2024, the PCCP guidance allows manufacturers to prospectively define the types of modifications they intend to make to their AI/ML-DSF and the methods they will use to assess those changes, all within the original marketing authorization [4]. This framework is a cornerstone of the FDA's "Total Product Lifecycle" approach, enabling rapid, safe, and effective iteration of AI models in the real world.

A PCCP typically requires two main components to be defined upfront: 1. **The "Algorithm Change Protocol"**: A detailed plan outlining the specific methodology for managing and controlling changes to the AI/ML algorithm. This includes the validation and testing procedures that will be used to ensure the modified device remains safe and effective. 2. **The "Specific Modifications"**: A description of the types of changes that are anticipated, such as updates to the input data, performance improvements, or new clinical claims [5].

The PCCP represents a significant shift from the traditional "locked" algorithm model, acknowledging that the value of AI in healthcare lies in its ability to continuously improve. By providing a clear, pre-approved path for iterative updates, the FDA aims to accelerate the deployment of safer, more effective AI/ML-DSFs while maintaining rigorous oversight. This framework is particularly critical for devices that learn from real-world data, where continuous monitoring and updating are essential for maintaining performance and addressing potential drift [10].

The European Union: MDR and the AI Act

In the European Union, the regulatory landscape is shaped by two major legislative instruments: the **Medical Device Regulation (MDR)** and the emerging **AI Act**.

Medical Device Regulation (MDR)

AI medical devices must first comply with the MDR (Regulation (EU) 2017/745), which imposes stringent requirements for clinical evidence, quality management systems, and post-market surveillance. The classification of an AI device under the MDR is risk-based, with higher-risk devices requiring greater scrutiny from a Notified Body [6]. The MDR's focus on clinical performance and safety remains the primary hurdle for market access.

The EU AI Act

The EU AI Act, which is expected to be fully implemented in the coming years, introduces a horizontal regulatory framework for AI across all sectors. AI systems intended to be used as a safety component of a medical device are classified as **"high-risk"** under the AI Act [7]. This designation imposes additional obligations on manufacturers, including: *Robustness and accuracy*

requirements. Data governance and quality standards. *Transparency and provision of information to users.* Human oversight provisions [8].

The challenge for manufacturers is ensuring seamless alignment between the specific requirements of the MDR and the broader, cross-sectoral demands of the AI Act. The MDR focuses on the device's safety and performance for its intended medical purpose, while the AI Act introduces fundamental requirements related to data quality, transparency, and human oversight for the underlying AI system [8]. This dual compliance obligation necessitates a highly integrated quality management system that addresses both medical device-specific risks and general AI-related risks, such as bias and lack of explainability. Furthermore, the EU's classification of AI medical devices as "high-risk" under the AI Act means they are subject to the most stringent conformity assessment procedures, often requiring third-party involvement and extensive documentation [11]. This complex regulatory environment underscores the need for proactive planning and a deep understanding of both medical and AI-specific legislation.

Key Regulatory Challenges and Future Directions

The regulatory environment for AI is still maturing, and several key challenges persist:

Bias and Fairness: *Ensuring that AI models are trained on diverse, representative data to prevent algorithmic bias that could lead to health inequities [9].* **Transparency and Explainability**: Regulators require a sufficient level of transparency (or "explainability") to understand how an AI model arrives at a decision, especially for high-risk applications. **Post-Market Surveillance**: *Developing effective methods for monitoring the performance of adaptive AI models once they are deployed in a real-world clinical setting.*

The global trend is moving toward a risk-based, adaptive, and harmonized approach. The FDA's PCCP and the EU's dual framework of the MDR and AI Act represent significant steps toward creating a predictable and safe environment for the next generation of AI-powered healthcare. Staying abreast of these evolving **AI medical device regulations** *is not just a compliance exercise, but a prerequisite for responsible innovation. The future of AI regulation is likely to involve greater international collaboration to harmonize standards, particularly around data governance and the validation of continuously learning algorithms, ensuring that innovation can thrive without compromising patient safety [12].*

*

References

[1] IMDRF. Software as a Medical Device (SaMD): Key Definitions*. [Online]. Available:*
https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-131209-samd-key-definitions-140901.pdf [2] Singh, R. et al. (2025). How AI is used in FDA-authorized medical devices. Nature Digital Medicine*. [Online]. Available: https://www.nature.com/articles/s41746-025-01800-1 [3] FDA.* De Novo Classification Request*. [Online]. Available: https://www.fda.gov/medical-*

devices/premarket-pathways/de-novo-classification-request [4] FDA. (2024). Marketing Submission Recommendations for Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions*. [Online]. Available: https://www.fda.gov/media/184856/download [5] Ketryx. (2024).* Understanding FDA Guidance on AI in Medical Devices and Predetermined Change Control Plans (PCCPs)*. [Online]. Available: https://www.ketryx.com/blog/understanding-fda-guidance-on-ai-in-medical-devices-and-predetermined-change-control-plans-pccps [6] European Commission.* Medical Devices Regulation (MDR)*. [Online]. Available: https://health.ec.europa.eu/medical-devices-regulation-eu-2017745_en [7] European Commission.* Artificial Intelligence in healthcare*. [Online]. Available: https://health.ec.europa.eu/ehealth-digital-health-and-care/artificial-intelligence-healthcare_en [8] Aboy, M. et al. (2024). Navigating the EU AI Act: implications for regulated digital medical products.* Nature Digital Medicine*. [Online]. Available: https://www.nature.com/articles/s41746-024-01232-3 [9] AHA. (2025). Keep an Eye on Clinical Validation Gaps in AI-Enabled Medical Devices.* AHA Center for Health Innovation Market Scan*. [Online]. Available: https://www.aha.org/aha-center-health-innovation-market-scan/2025-09-16-keep-eye-clinical-validation-gaps-ai-enabled-medical-devices [10] Ropes & Gray. (2024).* FDA Finalizes Guidance on Predetermined Change Control Plans*. [Online]. Available: https://www.ropesgray.com/en/insights/alerts/2024/12/fda-finalizes-guidance-on-predetermined-change-control-plans-for-ai-enabled-device [11] VDE. (2024).* Approval of AI-based medical devices in Europe*. [Online]. Available: https://www.vde.com/topics-en/health/consulting/approval-of-ai-based-medical-devices-in-europe [12] Palaniappan, K. et al. (2024). Global Regulatory Frameworks for the Use of Artificial Intelligence in Healthcare.* JMIR AI*. [Online]. Available: https://ai.jmir.org/2024/1/e46871/